• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Preparation of mucosal nanoparticles and polymer-based inactivated vaccine for Newcastle disease and H9N2 AI viruses

tetano

Editor, Senior Moderator
Vet World. 2017 Feb;10(2):187-193. doi: 10.14202/vetworld.2017.187-193. Epub 2017 Feb 14.
[h=1]Preparation of mucosal nanoparticles and polymer-based inactivated vaccine for Newcastle disease and H9N2 AI viruses.[/h] Naggar HM[SUP]1[/SUP], Madkour MS[SUP]1[/SUP], Hussein HA[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]AIM:[/h] To develop a mucosal inactivated vaccines for Newcastle disease (ND) and H9N2 viruses to protect against these viruses at sites of infections through mucosal immunity.
[h=4]MATERIALS AND METHODS:[/h] In this study, we prepared two new formulations for mucosal bivalent inactivated vaccine formulations for Newcastle and Avian Influenza (H9N2) based on the use of nanoparticles and polymer adjuvants. The prepared vaccines were delivered via intranasal and spray routes of administration in specific pathogen-free chickens. Cell-mediated and humoral immune response was measured as well as challenge trial was carried out. In addition, ISA71 water in oil was also evaluated.
[h=4]RESULTS:[/h] Our results showed that the use of spray route as vaccination delivery method of polymer and nanoparticles Montanide? adjuvants revealed that it enhanced the cell mediated immune response as indicated by phagocytic activity, gamma interferon and interleukin 6 responses and induced protection against challenge with Newcastle and Avian Influenza (H9N2) viruses.
[h=4]CONCLUSION:[/h] The results of this study demonstrate the potentiality of polymer compared to nanoparticles adjuvantes when used via spray route. Mass application of such vaccines will add value to improve the vaccination strategies against ND virus and Avian influenza viruses.


[h=4]KEYWORDS:[/h] H9N2; Newcastle; adjuvant; mucosal; nanoparticles; polymer

PMID: 28344402 PMCID: PMC5352844 DOI: 10.14202/vetworld.2017.187-193
 
Back
Top Bottom